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Abstract: Vascular basement membrane (VBM) derived molecules are regulators of certain biological activities such as 
cell growth, differentiation and angiogenesis. Angiogenesis is regulated by a systematic controlled balance between VBM 
derived antiangiogenic factors and proangiogenic growth factors. In the normal physiological state, equilibrium is maintained 
between the antiangiogenic and proangiogenic factors. The antiangiogenic factors (molecules), which are generated by the 
proteolytic cleavage of the VBM, include; α1 chain non-collagenous (NC1) domain of type XVIII collagen (endostatin) 
and the NC1 domains from the alpha chains of Type IV collagen considered as endogenous angiogenesis inhibitors. These 
collagen derived NC1 domains have a pivotal role in the regulation of tumor angiogenesis, thus making them attractive 
alternate candidates for cancer therapies. In this review we illustrate a comprehensive overview of the knowledge gained 
from the signaling mechanisms of Type IV collagen derived endogenous inhibitors in angiogenesis.
Keywords: VBM, vascular basement membrane; ECM, extra cellular matrix; MMP, matrix metalloproteinase; HUVEC, 
human umbilical vein endothelial cell; MLEC, mouse lung endothelial cells; SCC-PSA1, teratocarcinoma cell line; VEGF, 
vascular endothelial cell growth factor; bFGF, basic ﬁ  broblast growth factor; α1–α6(IV)NC1, non-collagenous α1–α6 
chains of Type IV collagen domains 
Introduction
Angiogenesis, the sprouting of capillaries from pre-existing blood vessels, or by splitting of blood 
vessels is among the key events in destructive pathological processes such as tumor growth, metastasis, 
arthritis, age related macular degeneration etc., as well as in physiological processes such as develop-
ment, organ growth, reproduction and wound healing (Folkman, 1995a). Folkman’s group ﬁ  rst reported 
a hypothesis that tumor growth is dependent on neovascularization or angiogenesis (Folkman, 1995a; 
Folkman, 1995b). The growth of tumors is strictly dependent on the neovascularization, and the inhibi-
tion of vascular supply to tumors can suppress tumor growth (Folkman, 1971; Hanahan and Folkman, 
1996). Solid tumors cannot grow beyond 2 to 3 mm in diameter without recruitment of their own blood 
supply, thus tumor angiogenesis results from a balance between endogenous activators [vascular endo-
thelial growth factor (VEGF), ﬁ  broblast growth factor (FGF), and platelet-derived growth factor (PDGF) 
etc.] and inhibitors [various antiangiogenic peptides generated from VBM or extracellular matrix (ECM) 
degradation by proteases] (Folkman, 1995a; Kieran et al. 2003; Folkman, 2003).
Endogenous angiogenesis inhibitors from ECM includes a large multifunctional ECM glycoproteins 
such as thrombospondin (Good et al. 1990), Endorepellin, a COOH terminal end of perlecan, (or per-
lecan domain V) (Yurchenco and O’Rear, 1994), Anastellin, a ﬁ  bronectin fragment, Fibulins (COOH 
terminal fragments corresponding to ﬁ  bulin 1D and the domain 111 of ﬁ  bulin 5) (Yi and Ruoslahti, 
2001; Albig and Schiemann, 2004). Endostatin, a 20 kDa fragment derived from the COOH-terminal 
non-collagenous domain of α1 chain of type XVIII collagen (O’Reilly et al. 1997) and Type IV col-
lagen derived α1 chain non-collagenous α1(IV)NC1, α2(IV)NC1, α3(IV)NC1 and α6(IV)NC1 domains 
(Petitclerc et al. 2000).
Non-ECM derived endogenous angiogenesis inhibitors includes angiostatin, a 38 to 45 kDa 
peptide from plasminogen, that contain homologous triple-disulﬁ  de bridged kringle domains, 1 to 4 
or 1 to 3 (Patterson and Sang, 1997; Cornelius et al. 1998). Circulating clotting factors in the blood 218
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are also known to play an important role in 
angiogenesis. These factors include Antithrombin 
III, a latent form of intact antithrombin (O’Reilly 
et al. 1999), Prothrombin kringle-2, is derived 
from cleavage of the COOH-terminal loop of 
antithrombin and the cleaved conformational 
changed molecule showing antiangiogenic and 
antitumorogenic activity (Lee et al. 1998). Tissue 
inhibitors of matrix metalloproteinases-2 
(TIMP-2) suppress MMP activity and ECM 
turnover (Brew et al. 2000; Jiang et al. 2002), 
2-Methoxyestradiol (2-ME) an endogenous 
estradiol metabolite (Mabjeesh et al. 2003), 
Vasostatin, a NH2-terminal domain of human 
Calreticulin inclusive of 1,180 amino acids (Pike 
et al. 1998; Pike et al. 1999), soluble Fms-like 
tyrosine kinase 1 (sFlt-1) or VEGFR1 (Kendall 
and Thomas, 1993), Troponin I (Tn I) derived 
from cartilage (Moses et al. 1999), Pigment 
epithelium-derived factor (PEDF), a non-
inhibitory member of the serpin superfamily 
(Volpert et al. 2002), Interferon α/β (INFα/β) 
(Lingen et al. 1998; Dinney et al. 1998), Chon-
dromodulin-I, a 25 kDa cartilage speciﬁ  c Non-
Collagenous-1 matrix protein (Kusafuka et al. 
2002), PEX, a non-catalytic COOH terminal 
hemopexin-like domain of MMP-2 (Brooks et al. 
1998), Prolactin fragment, 16 kDa and 8 kDa 
fragments generated from 23 kDa intact prolac-
tin (Ferrara et al. 1991), Interleukins (a family 
of leukocyte-derived proteins) (Strieter et al. 
1995b; Strieter et al. 1995a) and platelet factor-4 
(release from platelet α-granules during platelet 
aggregation) (Maione et al. 1990) etc.
This review will highlight some of the impor-
tant features of Type IV collagen-derived angio-
genic inhibitor molecules and address their 
integrin mediated signaling mechanisms in the 
regulation of abnormal neovascularization in 
tumors, that would explain how these endogenous 
angiogenesis inhibitors regulate angiogenic bal-
ance in the tumor bed.
Type IV Collagen Derived 
Angiogenesis Inhibitors
Type IV collagen is the most abundant constituent 
of the basement membrane (BM) that forms a 
network like structure in the extracellular matrix. 
Type IV collagen providing a scaffold in the BM 
with other macromolecules, such as laminins, 
heparan sulfate proteoglycans, ﬁ  bronectin, entactin 
and regulates the interaction with adhering cells 
(Timpl et al. 1981; Kuhn et al. 1981; Timpl, 1996). 
Type IV collagen is found normally only in the 
BM, but during pathogenesis, it is associated with 
tumor ﬁ  brosis and accumulates in the tumor inter-
stitium (Timpl et al. 1981; Kuhn et al. 1981). Type 
IV collagen is composed of six (α1 to α6) distinct 
gene products and their genomic localization 
shows a pair-wise head-to-head arrangements with 
a bi-directional promoter, that were mapped onto 
three different chromosomes (Hudson et al. 1993; 
Hudson et al. 1994; Kuhn, 1995). α1 and α2 chains 
are most abundant forms of   Type IV collagen 
found in most basement membranes (BM) (Hudson 
et al. 2003). Where as α3–α6 chains are found 
in kidney a specialized glomerular basement mem-
brane with speciﬁ  c functional properties (Hudson 
et al. 2003).
The [α1(IV)]2α2(IV) trimers contain a triple 
helical domain with binding sites for α1β1 and 
α2β1 integrins (Vandenberg et al. 1991). Initially 
in 1986, cells binding to Type IV collagen and its 
inhibition with Type IV collagen peptides has 
been demonstrated (Aumailley and Timpl, 1986; 
Tsilibary et al. 1990; Chelberg et al. 1990). Tsili-
bary in 1990, ﬁ  rst reported a peptide that was 
derived from non-collagenous domain (NC1) of 
the α1(IV) chain could promote adhesion of 
bovine aortic endothelial cells (Tsilibary et al. 
1990). The functional α1 and α2 Type IV collagen 
chains isolated from the Engelbreth Holm Swarm 
Sarcoma tumors inhibited capillary endothelial 
cell proliferation (Ries et al. 1995; Madri, 
1997).
The new functions for α2, α3 and α6 NC1 
domains of type IV collagen and their integrin 
ligands inhibiting angiogenesis and tumor growth 
in vivo reported in 2000 (Petitclerc et al. 2000). 
Later several laboratories worked on these mol-
ecules and further supported antiangiogenic and 
antitumorogenic activities of these NC1 domains 
(Kamphaus et al. 2000; Maeshima et al. 2000; 
Pasco et al. 2000; Colorado et al. 2000; Marneros 
and Olsen, 2001; Maeshima et al. 2002; Sudhakar 
et al. 2003; Hamano et al. 2003; Sudhakar et al. 
2005; Roth et al. 2005; Magnon et al. 2005; Borza 
et al. 2006; Boosani and Sudhakar, 2006; Boosani 
et al. 2007; Magnon et al. 2007). The molecular 
signaling mechanisms for regulation of angiogen-
esis by α1, α2, α3 and α6 NC1 domains of Type 
IV collagen are updated in this review. Under-
standing the mechanism(s) of action of such 219
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molecules would aid in unraveling their therapeutic 
applications.
α1(IV)NC1 or arresten
α1(IV)NC1 is one of the recently identiﬁ  ed endog-
enous inhibitors of angiogenesis. It is a 26-kDa 
molecule derived from the NC1 domain of the α1 
chain of Type IV collagen by proteases (Colorado 
et al. 2000; Sudhakar et al. 2005; Boosani et al. 
2006). The extensive studies from my laboratory 
and others suggest that α1(IV)NC1 functions via 
α1β1 integrin and blocks the binding of α1β1 
integrin to the Type IV collagen (Colorado et al. 
2000; Sudhakar et al. 2005). Integrin α1β1 is a 
collagen binding receptor that also binds to other 
basement membrane components such as laminin 
(Zutter and Santoro, 1990; Keely et al. 1995). Both 
α1 and β1 integrins are involved in angiogenesis 
(Senger et al. 2002). Using the neutralizing antibod-
ies for α1 integrin, angiogenesis associated with 
tumor growth could be suppressed. Blocking of 
α1β1 integrin interactions with ECM inhibits 
angiogenesis, which indicates that the integrins 
α1β1 acts as proangiogenic receptors (Senger et al. 
2002). Among the integrin receptors for collagen, 
α1β1 integrin activates the Ras/Shc mitogen 
activated protein kinase (MAPK) pathway promot-
ing cell proliferation (Senger et al. 2002). We 
demonstrated that α1(IV)NC1 binds to α1β1 inte-
grin in a collagen type IV dependent manner and 
mediates all of its antiangiogenic functions through 
this integrin and inhibits angiogenesis by inhibiting 
endothelial cell proliferation, migration and tube 
formation (Sudhakar et al. 2005; Boosani et al. 
2006). α1(IV)NC1 might also function via binding 
to heparan sulfate proteoglycans. Previously hepa-
ran sulfate proteoglycan was reported to bind to 
α1(IV)NC1 domain (Colorado et al. 2000). Sig-
niﬁ  cant halt in pathological angiogenesis and tumor 
growth was reported in α1 integrin knockout mice 
(Pozzi et al. 2000; Sudhakar et al. 2005). Whereas, 
α1(IV)NC1 had no effect in α1 integrin knockout 
mouse lung endothelial cells (Sudhakar et al. 2005). 
On the contrary, it signiﬁ  cantly inhibited prolifera-
tion of wild type mouse lung endothelial cells. Thus 
conﬁ  rms the signiﬁ  cance of integrin mediated sig-
naling of α1(IV)NC1 (Sudhakar et al. 2005).
In endothelial cells, ligand upon binding to 
integrins induces FAK phosphorylation, which 
serves as a platform for different downstream 
signals (Hynes, 2002; Kim et al. 2002; Sudhakar 
et al. 2003). Classical integrin ligand interactions 
are known to initiate intracellular signaling path-
ways, however some of such signaling events are 
reported to be inhibited by α1(IV)NC1 by binding 
to α1β1 integrin (Sudhakar et al. 2005). α1(IV)NC1 
inhibits phosphorylation of FAK when mouse lung 
endothelial cells (MLEC) are plated on collagen 
type IV matrix (Sudhakar et al. 2005). Similar 
inhibition of FAK phosphorylation was not 
observed with α1(IV)NC1 treatment in α1 integrin 
knockout MLEC cells (Sudhakar et al. 2005). 
Downstream to FAK, protein kinase B (Akt/PKB) 
plays an important role in endothelial cell survival 
signaling (Shiojima and Walsh, 2002; Sudhakar 
et al. 2003; Sudhakar et al. 2005). α1(IV)NC1 does
not inhibit Akt or phosphatidyl-3-kinase (PI3 
kinase) phosphorylation suggesting that α1(IV) NC1 
regulates migration of endothelial cells in an 
Akt-independent manner (Sudhakar et al. 2005).
Interestingly hypoxia induced factor alpha 
(HIF-1α) expression was inhibited by treatment of 
α1(IV)NC1 in hypoxic (lack of oxygen) endothelial 
cells (Sudhakar et al. 2005). HIF-1α is an oxygen-
dependent transcriptional activator, which plays 
crucial roles in the tumor angiogenesis (Semenza, 
2003; Lee et al. 2004). HIF-1α regulates cellular 
responses to physiological and pathological hypoxia, 
and studies demonstrate that HIF-1α is a potential 
target for tumor angiogenesis (Wu et al. 2003; Unruh 
et al. 2003). HIF-1α transcriptionally regulates 
VEGF expression in hypoxic cells and promotes 
angiogenesis in solid tumors (Kung et al. 2000; 
Miller et al. 1994; Carmeliet et al. 1998; Sudhakar 
et al. 2005). These ﬁ  ndings suggest that HIF-1α is 
a prime target for anticancer therapies. Our recently 
published ﬁ  ndings demonstrate that α1(IV)NC1 
binds to α1β1 integrin on endothelial cells and 
inhibits MAPK signaling, which results in inhibition 
of HIF-1α expression (Fig. 1) (Sudhakar et al. 
2005). Wild type tumor bearing mice when treated 
with α1(IV)NC1, decreased circulating VEGFR2 
positive endothelial cells, and such observations 
were not seen in MLECs of integrin α1 knockout 
mice. Measuring the number of circulating endo-
thelial cells is being evaluated as pharmacodynamic 
marker (Hurwitz et al. 2004). These studies provide 
a rationale for the use of α1(IV)NC1 as an inhibitor 
of HIF-1α and VEGF in hypoxic endothelial cells 
(Sudhakar et al. 2005). This hypoxic inhibitory 
activity might be exploited for antiangiogenic 
therapy in the treatment of cancer, but more pre-
clinical laboratory studies are needed.220
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α2(IV)NC1 or canstatin
Proteolytic degradation of   type IV collagen lib-
erates a 24-kDa peptide from α2 chain, called 
α2(IV)NC1, this peptide was reported to inhibit 
tumor associated angiogenesis (Petitclerc et al. 
2000). The exact mechanisms by which this NC1 
domain of  TypeIV collagen inhibits tumor angio-
genesis is not completely understood. α2(IV)NC1 
binds to the endothelial and tumor cell surface 
in an αVβ3 and αVβ5 integrin dependent manner 
(Panka and Mier, 2003; Roth et al. 2005; Magnon 
et al. 2005; Magnon et al. 2007). α2(IV)NC1 
competes with Type IV collagen of ECM for cell 
surface integrin binding and reverses the prolif-
erative and migratory effects induced by cell-
ECM interactions (Kamphaus et al. 2000). Thus, 
αVβ3 and αVβ5 integrins appear to mediate the 
antiangiogenic and antitumorgenic properties of 
α2(IV)NC1 (Magnon et al. 2005). In addition, 
researchers also determined that α2(IV)NC1 
binds to αVβ3 and αVβ5 integrins and induce 
apoptosis in endothelial and certain tumor cells 
(Magnon et al. 2005). α2(IV)NC1 inhibits the 
growth of many tumors in human xenograft 
mouse models, histological studies revealed 
decreased CD31 positive vasculature (Petitclerc 
et al. 2000; Kamphaus et al. 2000; Roth et al. 
2005; Magnon et al. 2005; Magnon et al. 
2007).
α2(IV)NC1 strongly inhibits the migration and 
proliferation of endothelial cells. Moreover, these 
events are mediated by an upstream event involv-
ing α2(IV)NC1 binding to αVβ3 and αVβ5 inte-
grins. Recent ﬁ  ndings have shown that α2(IV)NC1 
inhibits the phosphorylation of Akt, FAK, mam-
malian target of rapamycin (mTOR), eukaryotic 
initiation factor 4E binding protein-1 (4E-BP1), 
and ribosomal S6 kinase in cells (Panka and Mier, 
2003). Collectively, the available research informa-
tion suggests that, α2(IV)NC1 binds to αVβ3 and 
αVβ5 integrins and inactivates FAK down stream 
signaling, leading to suppression of cell prolifera-
tion and migration and thus leading to apoptosis 
(Kamphaus et al. 2000; Panka and Mier, 2003).
α2(IV)NC1 binds to αVβ3 and αVβ5 integrins 
and initiates two apoptotic pathways that include 
activation of caspase-8 and -9, (both initiators of 
the downstream apoptotic process) and leads to 
activation of caspase-3 (Roth et al. 2005, Magnon 
et al. 2005). α2(IV)NC1 activates caspase-8 by 
downregulation of Flip levels. Upregulation of 
Fas/Fas ligand triggers not only cell death directly 
through caspase-3 activation but also indirectly 
through mitochondrial damage via activation of 
caspase-9 within the apoptosome. On the other 
hand, phosphorylated FAK/PI3K is known to inac-
tivate the mitochondrial apoptotic pathway by 
inhibition of caspase-9 (Magnon et al. 2005). So, 
α2(IV)NC1 directly activates procaspase-9 through 
inhibition of the FAK/PI3K pathway and ampliﬁ  es 
the Fas-dependent pathway in mitochondria. Cas-
pase activation might be exploited for antitumoro-
genic therapy in the treatment of cancer.
Overall α2(IV)NC1 inhibits FAK/Akt signaling 
by binds to αVβ3 and αVβ5 integrins and induces 
distinct signaling pathways to activate caspase-3 
in endothelial or in tumoral cells. α2(IV)NC1 
initiates two apoptotic pathways, involving activa-
tion of caspase-8 and -9, leading to activation of 
caspase-3. (a) α2(IV)NC1 activates procaspase-9 
directly through inhibition of the FAK/PI3K/Akt 
pathway, and (b) activates caspase-3 by amplifying 
indirectly the mitochondrial pathway through Fas-
dependent caspase-8 activation. Where as in tumor 
Figure 1. Schematic illustration of signaling pathway mediated by 
α1(IV)NC1. α1(IV)NC1 binds to α1β1 integrin and cross talk with 
growth factor receptors, and inhibit phosphorylation of FAK. Inhibition 
of FAK activation leads to inhibition of Raf/ MEK/ERK1/2/p38 MAP 
kinase pathways that leads to inhibition of HIF-1α and VEGF expres-
sion which in turn results in inhibition of endothelial cell migration, 
proliferation and tube formation in proliferating endothelial cells.221
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cells α2(IV)NC1 activates caspase-3 only the 
mitochondrial pathway (Magnon et al. 2005) 
(Fig. 2).
α3(IV)NC1 or tumstatin
A 28-kDa proteolytic peptide liberated from the 
NC1 domain of α3 chain of Type IV collagen by 
MMP-9 and 2, has been shown to inhibit the pro-
liferation of melanoma and other epithelial tumor 
cell lines in vitro by binding to the CD47/αVβ3 
integrin complex (Monboisse et al. 1994; Han et al. 
1997; Shahan et al. 1999; Petitclerc et al. 2000; 
Hamano et al. 2003). In vivo over expression of 
α3(IV)NC1 domain in tumor cells inhibited their 
invasive properties in mouse melanoma model 
(Pasco et al. 2004; Pasco et al. 2005). α3(IV)NC1 
inhibits formation of new blood vessels in Matrigel 
plugs and suppresses tumor growth of human renal 
cell carcinoma and prostate carcinoma in mouse 
xenograft models and this is associated with in vivo 
endothelial cell speciﬁ  c apoptosis (Petitclerc et al. 
2000; Maeshima et al. 2000). The antiangiogenic 
activity of α3(IV)NC1 is localized to two distinct 
integrin binding region of the molecule that is 
separate from the region responsible for the antitu-
mor cell activity (Maeshima et al. 2000; Borza et al. 
2006; Boosani et al. 2007). αVβ3 binds in the NH2-
terminal end (54–132 amino acid region) of the 
α3(IV)NC1 that is associated with the antiangio-
genic activity and α3β1 binds in the COOH-
terminal end (185–203 amino acid region) that is 
associated with the antitumor activity (Shahan et al. 
1999; Floquet et al. 2004). These two distinct inte-
grin binding sites of α3(IV)NC1 mediating two 
distinct antiangiogenic and antitumorogenic activ-
ities was recently reported by Boosani et al. (Fig. 3) 
(Boosani et al. 2007).
Figure 2. Schematic illustration of distinct signaling pathways induced by α2(IV)NC1. α2(IV)NC1 binds to αVβ3 and αVβ5 integrins 
on endothelial and tumor cells, and initiates two distinct signaling pathways. (1) Inhibition of phosphorylation of FAK/PI-3K/eIF4E/4E-BP1. 
(2) Activation of caspase-8 and -9 leading to activation of caspase-3. α2(IV)NC1 activates pro-caspase-8 and -9 directly through inhibition 
of FAK/PI3K/Akt/mTOR pathway. α2(IV)NC1 also indirectly enhances the mitochondrial pathway through Fas dependent caspase-8 activa-
tion, which results in inhibition of protein synthesis, DNA damage and cell death.222
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The signaling mechanism involving inhibition 
of endothelial cell-speciﬁ  c protein synthesis by 
α3(IV)NC1 binding to αVβ3 integrin was reported 
previously (Maeshima et al. 2002; Sudhakar et al. 
2003). This mechanism has since been implicated 
in inhibition of tumor growth from several tumor 
cell lines such as CT26 (colon adenocarcinoma), 
LLC (Lewis lung carcinoma), renal cell carcinoma 
(786-O), prostate carcinoma (PC3), human prostate 
cancer (DU145), human lung cancer (H1299), and 
human ﬁ  brosarcoma (HT1080), by inhibiting tumor 
angiogenesis (Petitclerc et al. 2000; Miyoshi et al. 
2006; Borza et al. 2006; Maeshima et al. 2000). 
The antiangiogenic activity of α3(IV)NC1 upon its 
interaction with αVβ3 integrin, inhibit activation 
of FAK, PI3K, Akt/protein kinase B, mTOR 
pathways and prevents the dissociation of eIF4E 
protein from 4E-BP1 leading to the inhibition of 
Cap-dependent translation (Maeshima et al. 2002; 
Sudhakar et al. 2003). Furthermore, these ﬁ  ndings 
indicate the role for integrins in mediating cell 
speciﬁ  c inhibition of protein translation that sug-
gests a potential mechanism for the speciﬁ  c effects 
of α3(IV)NC1 on endothelial cells (Sudhakar et al. 
2003).
Recently our laboratory has identiﬁ  ed the sig-
naling mechanism mediated by α3(IV)NC1 that 
inhibits hypoxia induced cyclo-oxygenase-2 
(COX-2) expression in endothelial cells via FAK/
Akt/NFκB pathways, and leads to decreased tumor 
angiogenesis and tumor growth in an α3β1 integrin 
dependent manner (Boosani et al. 2007). COX-2 
is a key enzyme involved in conversion of arachi-
donic acid to prostaglandins (PGs) and other 
eicosanoids (Hla and Neilson, 1992). Two isoforms 
of COX were identiﬁ  ed; COX-1 is expressed con-
stitutively, whereas COX-2 is induced by a variety 
of factors, including cytokines, growth factors, and 
tumor promoters (Hla and Neilson, 1992; DuBois 
et al. 1994). Mitogens such as tumor necrosis fac-
tor, phorbol ester, lipopolysaccharide, or interleukin-1 
are known to increase the steady-state levels of 
COX-2 (Jones et al. 1993; Michiels et al. 1993). 
Hypoxia induces COX-2 expression by nuclear 
transcription factor-kappa B (NFκB) (Schmedtje 
et al. 1997; Tamura et al. 2002). There is ample 
evidence that COX-2 over expression contributes 
to carcinogenesis and that COX-2 disruption can 
both prevent and treat a variety of solid tumors 
(Wu et al. 2003; Wu et al. 2004; Tamura et al. 2002; 
Subbaramaiah et al. 1997). NFκB plays an essen-
tial role in many diseases such as AIDS, athero-
sclerosis, asthma, arthritis, diabetes, inﬂ  ammatory 
bowel disease, muscular dystrophy, stroke, viral 
infections, cancer and is a possible target of thera-
peutic intervention (Kumar et al. 2004; Shishodia 
and Aggarwal, 2004). NFκB may facilitate the 
induction of COX-2 by lipopolysaccharide and 
phorbol ester in concert with the nuclear factor-
interleukin-6 expression site and a cAMP respon-
sive element site in bovine aortic endothelial cells 
(Inoue et al. 1995; Yamamoto et al. 1995).
In endothelial cells, α3(IV)NC1 binds to α3β1 
integrins and inhibits NFκB signaling resulting in 
inhibition of COX-2 mediated signaling. It was 
further proved that expression of COX-2 was inhib-
ited in β3 integrin knockout endothelial cells upon 
treatment with α3(IV)NC1, indicating that COX-2 
mediated signaling is regulated through α3β1 and 
not by αVβ3 integrin (Boosani et al. 2007). Inter-
estingly COX-2 expression was not affected when 
Figure 3. Schematic illustration of different signaling pathway 
mediated by α3(IV)NC1. α3(IV)NC1 binds to αVβ3 and α3β1 integ-
rins, and inhibits phosphorylation of FAK. Inhibition of FAK activation 
leads to inhibition of FAK/PI-3K/eIF4E/4E-BP1 cap dependent trans-
lation. In addition α3(IV)NC1 inhibits NFκB mediated signaling in 
hypoxic conditions leading to inhibition of COX-2/VEGF/bFGF expres-
sion, resulting in inhibition of hypoxic tumor angiogenesis.223
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hypoxic α3 integrin knockout ECs were treated 
with α3(IV)NC1 protein, conﬁ  rming that COX-2 
expression was regulated by α3β1 integrin (Boosani 
et al. 2007). These ﬁ  ndings strongly suggest that 
α3(IV)NC1 has the ability to inhibit pro-inﬂ  ammatory 
factor COX-2, and inhibit tumor vasculature and 
tumor growth in an α3β1 integrin dependent man-
ner (Boosani et al. 2007). In addition to COX-2 
inhibition, the COX-2 regulated down stream 
VEGF and bFGF protein expression was also inhib-
ited upon α3(IV)NC1 treatment to endothelial cells 
(Boosani et al. 2007). COX-2 was also reported to 
play a key role in tumor angiogenesis (Leung et al. 
2003; Harris, 2002). Moreover, several investiga-
tors have demonstrated that blockade of the COX-
2 mediated pathway serves as a therapeutic beneﬁ  t 
in different cancer models (Gately and Kerbel, 
2003; Panka and Mier, 2003; Kunz and Ibrahim, 
2003). COX-2 regulates cellular responses to 
pathological conditions and studies have demon-
strated that COX-2 is a potential target for tumor 
angiogenesis (Kunz and Ibrahim, 2003; Gately and 
Kerbel, 2003; Kunz et al. 2003).
The antitumorogenic activity of α3(IV)NC1 
under hypoxic conditions in solid tumors was not 
clearly understood earlier. Our studies shed light on 
this mechanism by demonstrating that α3(IV)NC1 
binds to α3β1 integrins which inhibit COX-2 
expression both in vitro and in vivo (Boosani et al. 
2007). It is clear that inhibition of hypoxia induced 
angiogenesis by α3(IV)NC1 is a complex process 
requiring further investigation. Our previous ﬁ  nd-
ings indicate that there may be several targets for 
the inhibitory effects of α3(IV)NC1 on tumor-
angiogenesis, including or in addition to COX-2, 
VEGF and bFGF (Boosani et al. 2007).
In summary, the in vitro and in vivo observations 
support the role of αVβ3 and α3β1 integrins for 
the antiangiogenic activity of α3(IV)NC1. While 
both these integrins mediate tube formation in 
cultured ECs, α3β1 integrin mediates signaling 
events that influences downstream effects of 
COX-2 expression which appears to be central to 
the mechanism of α3(IV)NC1 antitumor activities. 
Our studies also demonstrate that α3(IV)NC1 
inhibits hypoxia induced angiogenesis by (1) inhib-
iting NFκB activation, leading to (2) inhibition of 
COX-2 expression, which in turn results in (3) 
down regulation of hypoxia induced VEGF/bFGF 
expression (Fig. 3) (Boosani et al. 2007). These 
ﬁ  ndings have potential implications of α3(IV)NC1 
for treatment of solid tumor growth, which depend 
critically on hypoxic angiogenesis. The decrease 
in COX-2 expression under hypoxia that results in 
decreased VEGF/bFGF expression will likely 
represent a primary molecular mechanism by 
which α3(IV)NC1 inhibit the pathological angio-
genesis that is essential to the growth of tumors 
(Boosani et al. 2007).
α6(IV)NC1
In addition to the NC1 domains of collagen IV 
α1,α2, α3 chains, α6(IV)NC1 domain also possesses 
antiangiogenic activity and inhibits tumor growth 
(Petitclerc et al. 2000), but a clear and extensive 
analysis of this molecule are yet to be unraveled.
Conclusions and Future Directions
Type IV collagen derived endogenous angiogenesis 
inhibitors bind to different cell surface integrins 
and exert their effects through multiple mechanisms 
that include induction of endothelial cells apoptosis, 
inhibition of migration, proliferation, tube forma-
tion of endothelial cells, and inhibit or alter the 
functions of proangiogenic growth factors. Three 
possible conclusions can be drawn from the signal-
ing mechanisms of  Type IV collagen derived angio-
genic inhibitors that are shown in Table 1. (1) All 
these collagen type IV derived inhibitors appears 
to exert their antiangiogenic effects by binding to 
speciﬁ  c cell surface integrins. (2) These inhibitors 
also block the binding of natural ligand/binding 
partners for proangiogenic receptors/molecules. (3) 
In addition, possibly by binding to its receptors, 
these inhibitors crosstalk with other cell surface 
receptors and activate speciﬁ  c caspase mediated 
signaling to regulate cell function (Panka and Mier, 
2003; Magnon et al. 2005).
Currently, more than 25 different endogenous 
circulating molecules (small proteins or peptides) 
are found to exist in the human body that functions 
as angiogenesis inhibitors. Circulating physiologi-
cal concentration of α3(IV)NC1 was reported in 
normal mice to be about 336 ng/ml, that was absent 
in α3 chain of  Type IV Collagen null mice (Hamano 
et al. 2003). Administration of 300 ng of recombi-
nant α3(IV)NC1 to physiological levels in α3 chain 
of  Type IV Collagen null mice with LLC tumors 
showed decrease tumor growth, the number of 
blood vessels and circulating endothelial cells to 
the wild-type baseline levels (Hamano et al. 2003; 
Sund et al. 2005). It is quite possible that genetic 
control of  the physiologic levels of these endogenous 224
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angiogenesis inhibitors might contribute to a critical 
line of defense against the conversion of dormant 
neoplastic events into a malignant phenotype of 
cancer.
Several angiogenic inhibitors including integrin 
αV antagonist EMD 121974, 2-methoxyestradiol 
(panzam) and, MMP-2 and -9 inhibitor COL-3 etc 
are currently in phase 1/2 human clinical trails 
(Jansen et al. 2004). Questions regarding resistance 
to these angiogenesis inhibitors do remain unan-
swered; however, a combination of radiation therapy 
with other antiangiogenic therapies may also prove 
to be clinically useful and effective. Further evalua-
tion through extensive laboratory studies on these 
molecules are needed to address the function of   Type 
IV collagen derived endogenous inhibitors of angio-
genesis to be considered for the clinical trials. Earlier 
lessons from preclinical trials of angiostatin, end-
ostatin, Thrombospondin-1 (ABT-510) and 2-ME 
suggest that more basic laboratory research studies 
are required to better understand the mechanism of 
actions associated with each of these endogenous 
angiogenesis inhibitor molecules. Presently, some 
of the anti-angiogenic agents such as Bevacizumab 
and several other VEGFR tyrosine kinase inhibitors; 
Vatalanib (PTK787/ZK 222584), Semaxanib 
(SU5416), Sunitinib (SU11248), Sorafenib (BAY 
43-9006) are in clinical trials (Hurwitz et al. 2004; 
Morabito et al. 2006). In the past few years several 
advances were made VBM derived endogenous 
angiogenesis inhibitors functional studies. VBM not 
only is an important structural component of the 
blood capillary, but it is also an important functional 
regulator of tumor angiogenesis and tumor growth. 
VBM in an assembled form performs completely 
new role compared with degraded form (exposed to 
different proteases). The degraded VBM modulate 
cellular behavior, hiding or exposing basement 
membrane integrin binding sequences. Therefore, 
VBM has become very good source of a collection 
of peptides or proteins that posses distinct activities 
with in the same primary sequence. These sequences 
are available at different stages during VBM struc-
tural changes; just like as the coagulation pathway 
proteins. Our understanding of how these collagen 
Type IV derived angiogenesis inhibitors regulate 
angiogenesis has just began compared to type XVIII 
collagen derived angiogenesis inhibitor or end-
ostatin. Further extensive laboratory studies are 
required to know how Type IV collagen derived 
molecules regulating cellular functions to halt tumor 
growth and tumor angiogenesis.
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